It is possible that such minor gene effects may be additive and particular combinations of polymorphisms from different genes may confer neuroprotection
Understanding Retatrutide: A New Hope for Weight Loss Retatrutide, an innovative weight loss medication, is currently not yet available commercially as it awaits FDA approval
Currently, no GLP-1 medication holds a UK licence for binge eating disorder, and NICE has not issued guidance recommending their use for this indication
For medical use under professional supervision
It will be important to consider the specific GLP1-RAs that have shown clear benefit in the reduction of MI risk when integrating them into contemporary primary and secondary ASCVD prevention guidelines
This growth is driven by clinical success of approved peptides, expanding applications, and continued pipeline development